natgillin/translations-raw huggingface dataset:
Select a different injection site each time you inject to avoid soreness.
Vsakokrat, ko injicirate zdravilo, izberite drugo mesto injiciranja, s čimer lahko preprečite bolečino.
Select a dose of 2 units by turning the dosage selector.
A. Nastavite odmerek 2 enoti tako, da zavrtite izbirnik odmerka.
Select a dose of 2 units by turning the dosage selector.
Nastavite odmerek 2 enoti tako, da zavrtite izbirnik odmerka.
Select a measuring device that has at least double volume of the calculated daily product volume.
Izberite merilno napravo z najmanj dvojnim volumnom izračunanega dnevnega volumna zdravila.
Select a new needle.
Izberite novo iglo.
Select a new needle.
Vzemite novo iglo.
Select a well lit, flat work surface, such as a table.
Izberite dobro osvetljeno, ravno delovno površino, kot je na primer miza.
Select an injection site for your first injection.
Izberite mesto injiciranja za vašo prvo injekcijo.
Select an injection site.
Izberite mesta injiciranja.
Select an injection site.
Izberite mesto injiciranja.
Select efficacy results from Study 1 in the hyaline vascular subgroup are summarised in Table 4.
Izbrani rezultati o učinkovitosti v podskupini s hialino vaskularnim histološkim podtipom iz Študije 1 so povzeti v preglednici 4.
Select one of the following hypodermic safety needles depending on the injection site and patient’s weight and attach the needle to the luer lock syringe containing the suspension for injection.
Glede na mesto injiciranja in telesno maso bolnika izberite eno od spodnjih varnostnih podkožnih igel in iglo pritrdite na injekcijsko brizgo z nastavkom Luer Lock, ki vsebuje suspenzijo za injiciranje.
Select one of the following hypodermic safety needles depending on the injection site and patient’s weight.
Glede na mesto injiciranja in telesno maso bolnika izberite eno od spodnjih varnostnih podkožnih igel.
Select the applicator size (or combination of applicators, for cats >7.5 kg) adapted to the cat’s weight.
Izberite primerno velikost aplikatorja (ali kombinacijo alplikatorjev za mačke težje od 7,5 kg), glede na telesno težo zdravljene živali.
Select the appropriate applicator size for the weight of the cat.
Izbira primerne velikosti aplikatorja mora temeljiti na telesni teži zdravljene živali.
Select the correct number and size of sachets according to the amount of product required.
Izberite pravilno število vrečk glede na potrebno količino izdelka.
Select the correct number of sachets according to the amount of product required.
Izberite pravilno število vrečk glede na potrebno količino zdravila.
Select the dose for the Safety Test.
Izberite odmerek za varnostni preizkus.
Select the injection site in the abdomen or thigh (except your navel or waistline).
Izberite mesto injiciranja na trebuhu ali stegnu (razen področje popka in pasu).
Select your dose
Izbira odmerka
Select your injection site.
Izberite mesto injiciranja.
Select your required dose (in the example below, the selected dose is 30 units).
Nastavite potrebni odmerek (v spodnjem primeru je nastavljen odmerek 30 enot).
Select your required dose by turning the dose selector forward.
Nastavite potrebni odmerek tako, da izbirnik odmerka zavrtite naprej.
Selected adverse drug reactions
Izbrani neželeni učinki
Selected adverse reactions that were reported in the recommended starting dose of 140 mg once daily are shown in Table 3b.
Izbrani neželeni učinki, o katerih so poročali pri uporabi priporočenega začetnega odmerka 140 mg enkrat na dan, so prikazani v preglednici 3b.
Selected laboratory abnormalities of at least moderate intensity (≥ Grade 2) that represent a worsening from baseline and are considered ADRs observed in HCV-infected patients treated with INCIVO combination treatment from the pooled data from the placebo-controlled Phase 2 and Phase 3 trials are presented in the table below:
Izbrani nenormalni laboratorijski izvidi najmanj zmerne jakosti (≥ 2. stopnje), ki predstavljajo poslabšanje začetnih vrednosti ter štejejo za neželene učinke, opažene pri bolnikih, okuženih s HCV in zdravljenih z zdravilom INCIVO pri kombiniranem zdravljenju, na podlagi združenih podatkov, dobljenih v s placebom nadzorovanih preskušanjih faze II in III, so navedeni v spodnji preglednici.
Selection of an alternate concomitant medication with no or minimal enzyme or transporter induction potential is recommended.
Priporočljivo je izbrati alternativno sočasno zdravilo, ki ne inducira ali ima minimalen vpliv na indukcijo encima ali transporterja.
Selection of an alternate concomitant medicinal product with no or minimal CYP3A enzyme inhibition potential, if possible, is recommended.
Priporočljivo je, da izberemo drugo sočasno zdravilo, ki nima potenciala za zaviranje CYP3A oz. je njegov tovrstni potencial minimalen.
Selection of an alternate concomitant medicinal product with no or minimal CYP3A inhibition potential, if possible, is recommended.
Priporočljivo je, da izberemo drugo sočasno zdravilo, ki nima potenciala za zaviranje CYP3A oz. je njegov tovrstni potencial minimalen.
Selection of an alternate concomitant medicinal product with no or minimal CYP3A4/5 induction potential is recommended.
Priporočljivo je izbrati kakšno drugo sočasno uporabljano zdravilo, ki ne inducira CYP3A4/5 oziroma je tovrstno induciranje minimalno.
Selection of an alternate concomitant medicinal product with no or minimal CYP3A4/5 inhibition potential is recommended.
Priporočljivo je izbrati kakšno drugo sočasno uporabljano zdravilo, ki ne zavira CYP3A4/5 oziroma je tovrstno zaviranje minimalno.
Selection of an alternate concomitant medicinal product with no or minimal P- gp induction potential should be considered.
Razmisliti je treba o alternativnem sočasnem zdravilu, ki P-gp inducira le malo ali pa sploh ne.
Selection of concomitant medicinal products with no or minimal CYP3A4/5 induction potential is recommended.
Priporočljiva je izbira takih sočasno uporabljanih zdravil, ki ne inducirajo CYP3A4/5 oziroma je tovrstno induciranje minimalno.
Selection of concomitant medicinal products with no or minimal CYP3A4/5 inhibition potential is recommended.
Priporočljiva je izbira takih sočasno uporabljanih zdravil, ki ne zavirajo CYP3A4/5 oziroma je tovrstno zaviranje minimalno.
Selection of patients for treatment with Provenge
Izbor bolnikov za zdravljenje z zdravilom Provenge
Selective MAO-B inhibitors should not be used at higher than recommended doses (e.g. selegiline 10 mg/day) when co- administered with Tasmar.
Selektivnih zaviralcev MAO-B se ne sme uporabljati v odmerkih, večjih od priporočenih (npr. selegilin 10 mg/dan), kadar se jemljejo skupaj z zdravilom Tasmar.
Selective serotonin reuptake inhibitors
Selektivni zaviralci prevzema serotonina
Selective Serotonin Reuptake Inhibitors (SSRIs)
Selektivni zaviralci ponovnega privzema serotonina (SSRI)
Selective Serotonin Reuptake Inhibitors (SSRIs)
Selektivni zaviralci ponovnega privzema serotonina (SSRI, Selective Serotonin Reuptake Inhibitors)
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)
SELEKTIVNI ZAVIRALCI PREVZEMA SEROTONINA (SSRIS)
Selexipag
eleksipag
Selexipag and its active metabolite are not expected to induce cytochrome P450 enzymes in the liver and kidney at clinically relevant concentrations.
Ne pričakuje se, da bi seleksipag in njegov aktivni presnovek inducirala encime citokroma P450 v jetrih in ledvicah v klinično pomembnih koncentracijah.
Selexipag and its active metabolite both undergo oxidative metabolism by CYP2C8 and CYP3A4.
Seleksipag in njegov aktivni presnovek CYP2C8 in CYP3A4 oksidativno presnovita.
Selexipag and its active metabolite do not inhibit cytochrome P450 enzymes at clinically relevant concentrations.
Seleksipag in njegov aktivni presnovek ne zavirata encimov citokroma P450 v klinično pomembnih koncentracijah.
Selexipag and its active metabolite do not inhibit transport proteins.
Seleksipag in njegov aktivni presnovek ne zavirata transportnih beljakovin.
Selexipag and the active metabolite are high-affinity IP receptor agonists with a high selectivity for the IP receptor versus other prostanoid receptors (EP1–EP4, DP, FP, and TP).
Seleksipag in aktivni presnovek imata veliko afiniteto za agoniste receptorja IP z veliko selektivnostjo za receptorje IP v primerjavi z drugimi receptorji prostanoidov (EP1–EP4, DP, FP in
Selexipag is hydrolysed by CES1 to yield its active metabolite, which is approximately 37-fold more potent than selexipag.
Seleksipag se s CES1 hidrolizira v aktivni presnovek, ki je približno 37-krat bolj močan kot seleksipag.
Selexipag is hydrolysed to its active metabolite by hepatic carboxylesterase 1 (CES1; see section 5.2).
Seleksipag se v svoj aktivni presnovek hidrolizira z jetrno karboksilesterazo 1 (CES1; glejte poglavje 5.2).
Selexipag is rapidly absorbed and is hydrolysed by CES1 in the liver to its active metabolite.
Seleksipag se hitro absorbira in v jetrih hidrolizira s CES1 v svoj aktivni presnovek.
Selexipag undergoes enzymatic hydrolysis of the acyl sulphonamide by CES1 to yield the active metabolite.
Seleksipag je predmet encimske hidrolize akilsulfonamida s pomočjo CES1, kar povzroči nastanek aktivnega presnovka.
Self adhesive matrix layer
Samolepilna matriksna plast
Self examination of your or your child’s skin is recommended.
Priporočamo samopregledovanje vaše kože ali kože vašega otroka.
Self Monitored Plasma Glucose
samoizmerjena glukoza v plazmi
Self- administration studies in rats, mice and monkeys have produced conflicting results, whereas tolerance to GHB as well as cross-tolerance to alcohol and baclofen has been clearly demonstrated in rodents.
Študije samoaplikacije pri podganah, miših in opicah so dale nasprotujoče si rezultate, medtem ko so lahko toleranco na GHB in navzkrižno toleranco z alkoholom in baklofenom pri glodalcih jasno pokazali.
Self-adhesive, paper label -Pramipexole Teva 0.088 mg Tablets
Samolepilna papirnata nalepka – Pramipeksol Teva 0,088 mg tablete
Self-adhesive, paper label – Pramipexole Teva 0.35 mg Tablets
Samolepilna papirnata nalepka – Pramipeksol Teva 0,35 mg tablete
Self-administration
Samoinjiciranje
Self-administration of Ovaleap should only be performed by patients who are well motivated, adequately trained and have access to expert advice.
Sami si lahko dajejo zdravilo Ovaleap samo bolniki, ki so dobro motivirani, ustrezno poučeni in imajo dostop do strokovnega nasveta.
Self-administration of Pergoveris should only be performed by patients who are well motivated, adequately trained and with access to expert advice.
Sami si lahko dajejo zdravilo Pergoveris samo bolniki, ki so dobro motivirani, ustrezno poučeni in imajo dostop do strokovnega nasveta.
Self-administration was feasible for most patients.
Samoinjiciranje je bilo izvedljivo pri večini bolnikov.
Self-injury
delirij,
Selfadministration of Ovitrelle should only be performed by patients who are adequately trained and have access to expert advice.
Samoinjiciranje zdravila Ovitrelle lahko izvajajo samo bolnice, ki so bile ustrezno podučene in imajo možnost nasveta strokovnjaka.
Self­measured FPG
Samoizmerjena glukoza v plazmi na tešče
Self­monitoring of blood glucose is not needed in order to adjust the dose of Victoza.
Za prilagoditev odmerka zdravila Victoza ni potrebna samokontrola glukoze v krvi.
Selincro 18 mg film-coated tablets nalmefene
Selincro 18 mg filmsko obložene tablete
Selincro does not require any special storage conditions.
Za shranjevanje zdravila Selincro niso potrebna posebna navodila.
Selincro has no or negligible influence on the ability to drive and use machines.
Zdravilo Selincro nima oziroma ima zanemarljiv vpliv na sposobnost vožnje in upravljanje s stroji.
Selincro helps to reduce your alcohol consumption by affecting processes in the brain that are responsible for your urge to continue drinking.
Zdravilo Selincro vam pomaga zmanjšati uživanje alkohola z vplivom na procese v možganih, ki so odgovorni za vašo potrebo po pitju.
Selincro is available in packs of 7, 14, 28, 42, 49 or 98 tablets in blister cards and in packs of 14 or 28 tablets in wallet cards.
Zdravilo Selincro je na voljo v pakiranjih po 7, 14, 28, 42, 49 ali 98 tablet v pretisnih omotih in v pakiranjih po 14 ali 28 tablet v zloženki.
Selincro is to be taken as-needed: on each day the patient perceives a risk of drinking alcohol, one tablet should be taken, preferably 1-2 hours prior to the anticipated time of drinking.
Zdravilo Selincro se mora jemati po potrebi: vsak dan, ko bolnik zazna, da obstaja tveganje pitja alkohola, mora vzeti eno tableto, po možnosti 1-2 uri pred predvidenim časom pitja.
Selincro may cause adverse reactions such as nausea, dizziness, insomnia, and headache.
Zdravilo Selincro lahko povzroči neželene učinke, kot so slabost, omotica, nespečnost in glavobol.
Selincro may cause side effects such as nausea, dizziness, insomnia, and headache.
Zdravilo Selincro lahko povzroči neželene učinke, kot so slabost, omotica, nespečnost in glavobol.
Semen donation
Darovanje sperme
Semi-translucent to opaque liquid following thaw from its frozen state.
Po odtajanju iz zamrznjenega stanja je to polprosojna do motna tekočina.
Semintra decreased protein in the urine within the first seven days after the start of treatment.
Zdravilo Semintra je zmanjšalo beljakovine v urinu v sedmih dneh po začetku uporabe.
Semintra is a veterinary medicine that contains the active substance telmisartan.
Semintra je veterinarsko zdravilo, ki vsebuje zdravilno učinkovino telmisartan.
Semintra is used to reduce proteinuria (protein in the urine).
Zdravilo Semintra se uporablja za zmanjševanje proteinurije (beljakovin v urinu).
Semintra was as effective as benazepril in reducing proteinuria in cats with chronic kidney disease.
Zdravilo Semintra je bilo pri zmanjševanju proteinurije pri mačkah s kroničnim ledvičnim obolenjem enako učinkovito kot benazepril.
Semintra was compared to benazepril (another medicine used in veterinary medicines to reduce proteinuria) in a field study involving 224 cats, aged mainly over 11 years, with chronic kidney disease.
Zdravilo Semintra so primerjali z benazeprilom (drugim zdravilom, ki se uporablja v veterinarski medicini za zmanjševanje proteinurije) v terenski študiji, v katero je bilo vključenih 244 mačk, večinoma starejših od 11 let s kroničnim ledvičnim obolenjem.
sensation in eye,
krogov, očesni
sensation in eye, Eyelid
občutek v očeh,
Sensation of fast or irregular heart beats, rapid heart beat, irregular heart beat, abnormal heart rhythm, heart failure
občutek hitrega ali nepravilnega utripanja srca, pospešen srčni utrip, nepravilen srčni utrip, nenormalni srčni ritem, srčno popuščanje
Sensation of heart beating (palpitations)
neprijetni občutki ob hitrem ali močnem utripanju srca (palpitacije)
Sensation of heart beating irregularly
občutek nepravilnega srčnega utripa,
sensation of heaviness
Ni znano
sensation of heaviness
občutek teže
Sensation of heaviness Urge to pass urine Kidney pain
pritisk po uriniranju bolečine v predelu ledvic pogosto uriniranje
Sensation of spinning (vertigo)
Občutek vrtenja (vrtoglavica)
Sensation of spinning (vertigo)
občutek vrtoglavice (vertigo)
Sensation of tingling or pricking
občutek mravljinčenja,
Sensation of tingling, tickling, pricking, or burning of the skin
občutek mravljinčenja, žgečkanja, pikanja ali žarenja na koži,
sensation, hypoaesthesia
občutek, hipestezija
Sensations of irregular and/or forceful beating of the heart
občutek nerednega in/ali silovitega utripanja srca
Senshio 60 mg film-coated tablets
Senshio 60 mg filmsko obložene tablete
Senshio 60 mg film-coated tablets Ospemifene
Senshio 60 mg filmsko obložene tablete ospemifen
Senshio 60 mg tablets Ospemifene
Senshio 60 mg filmsko obložene tablete ospemifen
Senshio contains lactose
Zdravilo Senshio vsebuje laktozo
Senshio contains the active substance ospemifene.
Zdravilo Senshio vsebuje zdravilno učinkovino ospemifen.
Senshio has been compared with placebo (a dummy treatment) in two main studies involving over 1,700 postmenopausal women with vulvovaginal atrophy.
Zdravilo Senshio so primerjali s placebom (zdravilom brez zdravilne učinkovine) v dveh glavnih študijah, v katerih je sodelovalo več kot 1 700 žensk po menopavzi z atrofijo vulve in vagine.
Senshio has no known or negligible influence on the ability to drive and use machines.
Zdravilo Senshio nima znanega vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Senshio has no or negligible influence on the ability to drive and use machines.
Zdravilo Senshio nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Senshio has not been formally studied in women with a prior history of breast cancer.
Zdravila Senshio niso uradno preučili pri ženskah z rakom dojke v anamnezi.
Senshio is for use in post-menopausal women only.
Zdravilo Senshio se uporablja samo za ženske po menopavzi.
Senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy (see section 5.1).
Zdravilo Senshio je indicirano za zdravljenje zmerne do hude simptomatske atrofije vulve in vagine (VVA, vulvar and vaginal atrophy) pri ženskah po menopavzi, ki niso primerne za lokalno vaginalno zdravljenje z estrogenom (glejte poglavje 5.1).
Senshio is indicated for use only in postmenopausal women.
Zdravilo Senshio je indicirano samo pri ženskah po menopavzi.
Senshio may increase the incidence of hot flushes and is not effective in reducing hot flushes associated with oestrogen deficiency.
Zdravilo Senshio lahko poveča incidenco vročinskih oblivov in ni učinkovito pri zmanjševanju vročinskih oblivov, povezanih s pomanjkanjem estrogena.
Senshio must also not be used in women who have or who are suspected of having breast cancer or another cancer that is sex-hormone dependent such as endometrial cancer (cancer of the womb).
Zdravila Senshio prav tako ne smejo uporabljati ženske z rakom dojke ali sumom na raka dojke; isto velja za druge vrste raka, ki so odvisne od spolnih hormonov, kot je rak endometrija (rak maternice).
Senshio should be discontinued at least 4 to 6 weeks prior to and during prolonged immobilisation (e.g., post-surgical recovery, prolonged bed rest).
Zdravilo Senshio je treba ukiniti vsaj 4 do 6 tednov pred dolgotrajno imobilizacijo in med njo (npr. okrevanje po operaciji, dolgotrajno ležanje v postelji).
Senshio should only be continued as long as the benefit outweighs the risk.
Zdravljenje z zdravilom Senshio se sme nadaljevati le tako dolgo, dokler so koristi večje od tveganj.
Senshio was shown to improve symptoms of vulvovaginal atrophy in postmenopausal women when compared with placebo.
Dokazano je bilo, da zdravilo Senshio izboljša simptome atrofije vulve in vagine pri ženskah po menopavzi, ko so ga primerjali s placebom.
Sensitisation or severe local irritation
Preobčutljivost ali hudo lokalno draženje
Sensitivity of the skin to sun light
prevelika občutljivost kože na sončno svetlobo
Sensitivity of the virus to INTELENCE at screening was required.
Ob začetku študije je bilo potrebno dokazati občutljivost na zdravilo INTELENCE.
Sensitivity score (GSS) §
Rezultat občutljivosti (GSS) §
Sensitivity score (GSS) §
Rezultat občutljivosti (GSS)§
Sensitivity to light
občutljivost na svetlobo
Sensitivity to light
občutljivost na svetlobo,
Sensitivity to sunlight.
občutljivost za sončno svetlobo,
Sensitivity, numbness, tingling or burning sensation of the skin, or pain in the hands or feet due to nerve damage, dizziness, trembling, headache, loss of or change in the sense of taste;
občutljivost, odrevenelost, mravljinčenje kože ali pekoč občutek na koži, bolečina v dlaneh ali stopalih zaradi poškodovanih živcev, omotica, tresenje, glavobol, izguba ali sprememba sposobnosti okušanja;
Sensitivity, numbness, tingling or burning sensation of the skin, or pain in the hands or feet, due to nerve damage
povečana občutljivost, odrevenelost, mravljinci ali pekoč občutek na koži ali bolečine v dlaneh in stopalih, zaradi poškodbe živca
Sensitivity, shyness, and social withdrawal disorder specific to childhood or adolescence
občutljivost, sramežljivost, socialni umik pri otrocih ali mladostnikih
Sensory disturbance (paresthesia, dysesthesia,
motnje čutil (parestezija, disestezija,
Sensory disturbance (paresthesia, dysesthesia,
nenormalnosti čutil (parestezija, disestezija, oralna
Sensory disturbance, hyperaesthesia
motnje čutil, hiperestezija
Sensory loss
izguba čutov
Sensory peripheral neuropathy is a class effect of the vinca alkaloids.
Senzorična periferna nevropatija je učinek alkaloidov rožnatega zimzelena.
Separate barrel and plunger and rinse both with water.
Ločiti je treba telo in bat in oba splakniti z vodo.
Separate injection sites must be used if more than one vaccine is administered at the same time.
Pri sočasnem cepljenju z več cepivi morate izbrati ločena mesta injiciranja.
Separate injection sites must be used if more than one vaccine is being administered at the same time.
Če se daje hkrati več cepiv, je treba uporabiti ločena mesta injiciranja.
Separate one capsule: tear along the cutting lines to separate one “pocket” from the strip.
Ločite eno kapsulo: odtrgajte vzdolž zarezanih črt, da boste en "žep" ločili od traku.
Separate one individual blister cell from the rest of the blister by gently tearing along the perforations around it.
Ločite posamezno pretisno celico od preostalega dela pretisnega omota, tako da nežno pretrgate perforacijsko linijo okoli celice.
Separate one individual blister cell from the rest of the strip by gently tearing along the perforations around it.
Ločite posamezno pretisno celico od preostalega dela traka, tako da nežno pretrgate perforacijsko linijo okoli celice
Separate one of the blister units from the blister card by tearing apart at the perforations.
Eno enoto pretisnega omota ločite od kartice s pretisnimi omoti tako, da jo odtrgate po perforaciji.
Separate one of the blisters from the blister card by tearing along the perforation.
Po perforaciji odtrgajte eno enoto s pretisnega omota.
Separate preparations of emtricitabine and tenofovir disoproxil are available for treatment of HIV-1 infection if it becomes necessary to discontinue or modify the dose of one of the components of Emtricitabine/Tenofovir disoproxil Zentiva.
Posamezni pripravki emtricitabina in dizoproksiltenofovirata so na voljo za zdravljenje okužbe z virusom HIV–1, če je treba prekiniti terapijo ali prilagoditi odmerek ene od učinkovin zdravila Emtricitabin/dizoproksiltenofovirat Zentiva.
Separate preparations of emtricitabine and tenofovir disoproxil fumarate are available for treatment of HIV-1 infection if it becomes necessary to discontinue or modify the dose of one of the components of Truvada.
Posamezni pripravki emtricitabina in dizoproksiltenofovirijevega fumarata so na voljo za zdravljenje okužbe z virusom HIV–1, če je treba prekiniti terapijo ali prilagoditi odmerek ene od učinkovin zdravila Truvada.
Separate syringe and vial
Injekcijsko brizgo ločite od viale
Separate the adaptor from the syringe (figure 2).
Ločite adapter od brizge (slika 2).
Separate the blister pack at perforations.
Ločite pretisni omot na perforacijah.
Separate the empty solvent vial and blue part from the clear part by unscrewing anti-clockwise.
Odstranite prazno vialo vehikla in modri del s prozornega dela, tako da ju obračate v nasprotni smeri vrtenja urinega kazalca.
Separate the morning and evening doses from the capsule card.
Jutranji in večerni odmerek odtrgajte od tablice.
Separate the syringe from the adapter.
Odstranite brizgo iz nastavka.
Separate transfer system.
Ločen sistem za prenos.
Separation distance according to frequency of transmitter
Razdalja glede na frekvenco oddajnika
Sepioglin 15 mg tablets are white, round, flat tablets, with “15” embossed on one side and a diameter of approximately 5.5 mm.
Zdravilo Sepioglin 15 mg je na voljo v obliki belih, okroglih, ploščatih tablet, z oznako ‚15‘, odtisnjeno na eni strani, in približno 5,5-milimetrskim premerom.
Sepioglin 30 mg tablets
Sepioglin 30 mg tablete